Mitraclip Secondary Mr denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for mitraclip secondary mr are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied MitraClip for Secondary Mitral Regurgitation as Experimental

An experimental or investigational denial means BCBS concluded that MitraClip for secondary (functional) mitral regurgitation lacks sufficient evidence of clinical benefit to meet its coverage criteria under its medical policy. This denial is distinct from the FDA-approval question: MitraClip holds FDA approval for both primary and secondary MR, but a payer's "experimental" determination is based on its own internal evidence threshold, not the agency's approval status alone.

## Why This Denial Is Appealable

MitraClip has an FDA-approved indication that explicitly includes patients with secondary MR meeting defined anatomical and clinical criteria. Major cardiology societies — including those whose guidelines govern heart failure and structural heart disease — have addressed transcatheter edge-to-edge repair in their published recommendations. When BCBS's medical policy diverges from those positions, external reviewers frequently side with the treating physician. The appeal should anchor on (a) the FDA label, (b) the applicable ACC/AHA or Heart Failure Society guideline organization's current position, and (c) your physician's documentation that your anatomy and clinical status match the approved indication.

## Federal Appeal Framework

• Internal appeal: File within the plan's deadline (typically 180 days). Decisions required within 30 days (pre-service) or 60 days (post-service).
• External review (ACA §2719 / ERISA §503): Experimental/investigational denials are expressly subject to independent external review under federal rules. Request external review within approximately four months of the final internal denial. An accredited Independent Review Organization (IRO) applies generally accepted clinical standards — not just the plan's policy.
• Expedited review: Available if clinical urgency exists; typically decided within 72 hours.

## Documentation to Gather

1. FDA labeling: The current MitraClip Instructions for Use (IFU) confirming the secondary MR indication and anatomical eligibility criteria. 2. Imaging confirmation: Echocardiogram establishing that your anatomy meets the IFU criteria — consult your cardiologist for the specific measurements required. 3. Heart failure treatment history: Documentation that heart failure therapies have been optimized prior to the procedure request. 4. Guideline citations: A prescriber letter referencing the relevant ACC, AHA, or Heart Failure Society guideline organization's current class of recommendation for TEER in secondary MR. 5. Heart team assessment: A multidisciplinary team note confirming surgical risk evaluation and patient selection rationale.

## Criteria-Mapping Structure

Obtain BCBS's medical policy for transcatheter mitral valve repair and the MitraClip FDA labeling. Map every stated requirement:

| Policy / Label Criterion | Chart Evidence | |---|---| | FDA-approved indication met | IFU excerpt + imaging report with anatomy confirmed | | Guideline-supported use | Prescriber letter citing guideline organization + class | | Surgical risk assessment | Heart team note / STS risk score category | | Symptomatic heart failure on GDMT | Medication list + functional status note | | Anatomical eligibility | Echo measurements interpreted by structural cardiologist |

An IRO reviewing this appeal will compare BCBS's evidence threshold against the FDA label and published society guidelines — these form the strongest rebuttal to an experimental classification.